A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 4, 2003, Pages 1433-1441

  Mazzaferri, Ernest L ^a,o   Robbins, R J ^b   Spencer, C A ^c   Braverman, L E ^d   Pacini, F ^e   Wartofsky, L ^f   Haugen, B R ^g   Sherman, S I ^h   Cooper, D S ⁱ   Braunstein, G D ^j   Lee, S ^d   Davies, T F ^k   Arafah, B M ^l   Ladenson, P W ^m   Pinchera, A ⁿ  

^a UNIVERSITY OF FLORIDA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d BOSTON MEDICAL CENTER   (United States)

^e UNIVERSITY OF SIENA   (Italy)

^f WASHINGTON HOSPITAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ SINAI HOSPITAL OF BALTIMORE   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k MOUNT SINAI MEDICAL CENTER   (United States)

^l UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^m JOHNS HOPKINS HOSPITAL   (United States)

ⁿ UNIVERSITY OF PISA   (Italy)

^o NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ALGORITHM; CANCER DIAGNOSIS; CONFERENCE PAPER; DIAGNOSTIC IMAGING; ECHOGRAPHY; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; NECK; PATIENT MONITORING; PRIORITY JOURNAL; THORAX RADIOGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT PLANNING; WHOLE BODY SCINTISCANNING;

CARCINOMA, PAPILLARY; HUMANS; IODINE RADIOISOTOPES; NEOPLASM METASTASIS; NEOPLASM, RESIDUAL; RECOMBINANT PROTEINS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 0037849895     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2002-021702     Document Type: Conference Paper

References (49)

1. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 83:2638-2648
3. Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller AB, Cleeg L, Edwards BK 2000 SEER Cancer Statistics Review, 1973-1997. Bethesda, MD: National Cancer Institute
4. Cady B, Cohn K, Rossi RL, Sedgwick CE, Meissner WA, Werber J, Gelman RS 1983 The effect of thyroid hormone administration upon survival in patients with differentiated thyroid carcinoma. Surgery 94:978-983
5. Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S 2000 Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 89:202-217
6. Holzer S, Reiners C, Mann K, Bamberg M, Rothmund M, Dudeck J, Stewart AK, Hundahl SA 2000 Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer 89:192-201
7. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178
8. Mazzaferri EL 1999 NCCN thyroid carcinoma practice guidelines. Oncology 13(Suppl 11A):391-442
9. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho MN, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon III HR 1998 Prospective multicenter study of thyroid carcinoma treatment. Initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry. Cancer 83:1012-1021
10. Van De Velde CJH, Hamming JF, Goslings BM, Schelfhout LJDM, Clark OH, Smeds S, Bruining HA, Krenning EP, Cady B 1988 Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 24:287-292
11. Baldet L, Manderscheid JC, Glinoer D, Jaffiol C, Coste Seignovert B, Percheron C 1989 The management of differentiated thyroid cancer in Europe in 1988. Results of an international survey. Acta Endocrinol (Copenh) 120:547-558
12. Solomon BL, Wartofsky L, Burman KD 1996 Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 81:333-339
13. Cady B 1997 Our AMES is true: how an old concept still hits the mark or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 174:462-468
14. Hay ID 1990 Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 19:545-576
15. Wong JB, Kaplan MM, Meyer KB, Pauker SG 1990 Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 19:741-760
16. 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract 7:202-220
17. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall JR, Ain KV, Dorfman SG 1996 Treatment guidelines for patients with thyroid nodules and well- differentiated thyroid cancer. Arch Intern Med 156:2165-2172
18. British Thyroid Association 2002 Guidelines for the management of differentiated thyroid cancer in adults. http://www.british-thyroid-association.org/guidelines.htm
19. Cady B, Sedgwick CE, Meissner WA, Bookwalter JR, Romagosa V, Werber J 1976 Changing clinical, pathologic, therapeutic, and survival patterns in differentiated thyroid carcinoma. Ann Surg 184:541-553
20. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058
21. American Joint Committee on Cancer 1992 Head and neck tumors. Thyroid gland. In: Beahrs OH, Henson DE, Hutter RVP, Myers MH, eds. Manual for staging of cancer. Philadelphia: J. B. Lippincott, 53-54
22. Demers LM, Spencer CA 7-13-2002 Laboratory support for the diagnosis and monitoring of thyroid disease http://www.nacb.org/lmpg/thyroidLMPG.stm
23. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121-1127
24. Spencer CA, Wang CC 1995 Thyroglobulin measurement. Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 24:841-863
25. Clark PM, Beckett G 2002 Can we measure serum thyroglobulin? Ann Clin Biochem 39:196-202
26. Spencer CA, Takeuchi M, Kazarosyan M 1996 Current status and performance goals for serum thyroglobulin assays. Clin Chem 42:164-173
27. Mariotti S, Barbesino G, Caturegli P, Marinó M, Manetti L, Pacini F, Centoni R, Pinchera A 1995 Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal. J Clin Endocrinol Metab 80:468-472
28. Robbins RJ, Chon JT, Fleisher M, Larson S, Tuttle RM 2002 Is the serum thyroglobulin response to recombinant human TSH sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 87:3242-3247
29. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ 1994 Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98-105
30. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon III HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
31. David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, Busutti L, degli Uberti EC 2001 Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. J Nucl Med 42:1470-1475
32. Vitale G, Lupoli GA, Ciccarelli A, Fonderico F, Klain M, Squame G, Salvatore M, Lupoli G 2002 The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre. Clin Endocrinol (Oxf) 56:247-252
33. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490-1498
34. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT 2002 Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. Thyroid 12:37-43
35. Pacini F, Mollnaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690
36. Wartofsky L 2002 Management of low risk well differentiated thyroid cancer based only upon thyroglobulin measurement after recombinant human thyrotropin. The rhTSH-Stimulated Thyroglobulin Study Group. Thyroid 12:121-134
37. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625
38. Torrens JI, Burch HB 2001 Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 30:429-467
39. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499-1501
40. Pacini F, Agate L, Ellsei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097
41. Schlumberger MJ 1999 Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22(Suppl 11):3-7
42. Schlumberger M, Mancusi F, Baudin E, Pacini F 1997 131-I Therapy for elevated thyroglobulin levels. Thyroid 7:273-276
43. Mazzaferri EL 1995 Treating high thyroglobulins with radioiodine. A magic bullet or a shot in the dark? J Clin Endocrinol Metab 80:1485-1487
44. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967
45. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C 1987 Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28:1888-1891
46. Pineda JD, Lee T, Ain K, Reynolds J, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488-1492
47. Fatourechi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA 2002 Lack of impact of radioiodine therapy in Tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. J Clin Endocrinol Metab 87:1521-1526
48. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins R 2001 Resistance of 18-F-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioiodine. Thyroid 11:1169-1176
49. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097